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ABSTRACT 
Objective: To evaluate the level of inflammatory factors of erythrocyte sedimentation rate and reactive 
protein C in benign and malignant thyroid nodules. Material and Methods: In this case-control study, 
patients who were referred because of an enlarged thyroid gland were selected, patients who had undergone 
surgery for the thyroid nodule were included in the study. Erythrocyte sedimentation rate and reactive 
protein C were measured before surgery in patients who were candidates for thyroid surgery. The 
histopathological records of patients were retrospectively reviewed. Relevant cases had a cytological 
evaluation of thyroid nodules by fine-needle aspiration cytology (FNAC). The mean of ESR / CRP in both 
groups was compared using an independent t-test (p>0.05). Results: In malignant tumor type, in all 
patients, with Pill (PTC), analyzes in the malignant group showed a significant difference between the mean 
ESR / CRP in both groups with and without thyroid history. Sub-analyzes in the malignant group were 
significantly different between the mean ESR / CRP in both groups with and without thyroid histories 
(p=0.009) (40.16 ± 28.81). The association between ESR and CRP, ESR / CRP and tumor size, ESR / CRP 
and age in each group as well as in the whole patients were evaluated using Pearson correlation test, which 
showed a positive association between ESR age and ESR (p=0.024, r=0.375). In the malignant group, a 
negative correlation was found between the age and the CRP rate (p=0.027, r=-0.441), and in the total 
patients between the age and the rate (ES=0.043, r=-0.256). Conclusion: Factors such as ESR and CRP, 
which are considered acute phase reactors and their levels increase in acute inflammatory conditions, may 
not have a significant increase in chronic inflammatory conditions and malignancies. 
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Introduction 
The development of thyroid nodules (overgrowth of normal thyroid tissue, thyroid cyst, chronic 
inflammation of the thyroid, multinodular goiter, thyroid cancer, iodine deficiency) is a common clinical 
problem and is found on physical examination and in more than 25% of cases using diagnostic methods such as 
sonography [1]. These nodules are important for malignancy. Thyroid malignancies are the most common 
endocrine malignancies, and 5 to 10 percent of medically considered thyroid nodules are malignant. On the 
other hand, in most studies performed on operated nodules, 10% of them have been malignant in pathology 
examination [2]. 
A higher incidence of malignancy in about 20 patients treated with surgery indicates a preoperative 
effort in selecting patients and does not show an accurate picture of the normal course of all thyroid nodules in 
the general population [3]. With a 5 to 1 chance for benign nodules, there is a greater need for preoperative 
differentiation between benign and malignant nodules. Therefore, to properly select patients for surgery, it is 
necessary to differentiate between benign and malignant nodules using different methods [2]. 
Among the various diagnostic methods, including radioisotope scanning, ultrasonography, and 
thyroid suppressant therapy response evaluation, the fine needle aspiration (FNA) method has been widely 
accepted as a simple, safe, and accurate method for evaluating thyroid nodules [4]. 
The palpable thyroid nodules are found in 5% of adults [5]. Most palatable nodules have a diameter 
greater than 1 cm. But the ability to touch the nodule is affected by factors such as the location of the nodule in 
the thyroid (superficial or deep), the neck of the anatomy, and the observer's experience. Susceptible methods 
such as computed tomography (CT), ultrasonography studies show thyroid nodules in more than 50% of 
people over 50 [6,7]. 
Most patients with thyroid nodules have normal thyroid function tests. If the thyroid-stimulating 
hormone (TSH) is low, a radionuclide scan is done indicating whether the nodule is hot or not because the 
nodules increase the excessive removal of thyroid ultrasonography due to the following reasons [8]: 
ultrasonography confirms that the palpable nodule is a nodule. About 15% of the palpable nodules are not 
confirmed by imaging, so further evaluation is not required [9]. If there are more palpable nodules, based on 
their imaging findings and their size, ultrasonography will assess the need for fine-needle aspiration (FNA) 
[10]. Ultrasonography facilitates decision-making about FNA by determining the shape and size of the nodule 
[11]. 
Nodular malformation is a disruption of thyroid cells' growth, often associated with gradual fibrosis. 
How to treat and control goiter based on its cause is different in patients. Therefore, after recognizing the 
thyroid gland's size in a physical examination, further assessment is needed to diagnose the cause. The term 
goiter is called the thyroid gland. Biosynthesis defects, iodine deficiency, autoimmune diseases and nodular 
diseases, each with different mechanisms, lead to goiter the creation. Graves' disease and Hashimoto's thyroids 
are also associated with goiter [9]. 
Thyroid carcinoma is the most common malignancy in the endocrine system. Malignant tumors 
derived from follicular epithelium are classified according to their histological characteristics. Distinct tumors 
like papillary thyroid carcinoma or follicular thyroid carcinoma are often curable and curable, and their 
prognosis is good if the disease is detected at an early stage. In contrast, anaplastic thyroid cancers are invasive 
and have a poor response to treatment. The prognosis is also weak [12]. 
Recently, some of the mechanisms that make up the relationship between inflammation and tumor are 
known. The small inflammatory environment of neoplastic tissues is characterized by leukocytes in the 
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supporting stroma and tumor cells, macrophages, dendritic cells, mast cells, and T cells distributed distinctly 
[13]. Several cytokines, tumor necrosis factor and chemokines produced by tumor cells and tumor-associated 
leukocytes and platelets can produce an aggressive phenotype [14]. 
Tumor-associated macrophages (TAMs) are major leukemia infiltrations that are initially called 
inflammatory chemokines {e.g., CC chemokine ligand 2 (CCL-2), and then held by cytokines present in a small 
tumor environment [13]. For example, Tumor-associated macrophages, vascular endothelial growth factor A, 
colony-stimulating factor-1, in response to cytokines such as interleukin-10, transforming growth factor β1, 
and macrophage colony-stimulating factor initiates tumors and progresses in the formation of stroma, and in 
times the density of tumor-associated macrophages increases in advanced thyroid cancers [8]. 
Previous authors investigated the link between blood CRP and cancer risk and whether increasing 
CRP could be a factor in cancer and found that 97% of participants had a CRP level below 10 mg / L. The 
mean plasma CRP levels (IQR 1.14-2.51) were 1.53 mg / L and 34% of participants had CRP > 2 mg / L [15]. 
The strong link between blood CRP levels and cancer risk may be due to 1) Increased CRP levels 
cause cancer, 2) Cancer increases CRP levels, and 3) Inflammation increases both CRP levels and cancer risk. 
Epidemiological studies of genetics (randomized controlled trials) examining the relationship between genetic 
polymorphism and cancer risk by considering blood CRP levels suggest that high CRP levels do not cause 
cancer. The lack of causality between elevated CRP levels and increased cancer risk does not invalidate the 
clinical application of mild CRP levels to predict cancer risk and treat cancer patients [16]. 
Growing evidence suggests inflammation is the seventh most important cancer characteristic that 
inflammation is associated with many malignancies' progression and prognosis. Red blood cell deposition and 
reactive protein C, as two indicators of inflammation, have often been reported in the development of solid 
cancers, but little research has been done on thyroid disease [17]. In this study, the level of inflammatory 
factors of Erythrocyte Sedimentation Rate and reactive protein C, which are commonly measured in clinical 
practice and are indicative of inflammation, in benign and malignant thyroid nodules were investigated. 
 
Material and Methods 
Research Design 
In this cross-sectional analytical study, 100 patients with cold thyroid nodules referring to Shahid 
Beheshti Hospital of Qom were studied and the result of pathology in FNA and surgery in patients was 
compared. 
 
Subjects 
Patients who were referred to the Thyroid Gland Department were selected using a purpose-based 
sampling method. ESR / CRP was measured before surgery in patients who were candidates for thyroid 
surgery. According to the pathology report, thyroid nodules were divided into benign (control) and malignant 
nodules (the case group). The required number of samples in each group was 30, and the standard deviation in 
each group was considered to be 5.7 according to the previous study [18], but the two groups were matched in 
terms of age, sex, and finally, the levels of ESR and CRP were compared in two groups. 
The criteria for entry in this study were patients with a history of cold thyroid nodules patients who 
had undergone surgery due to thyroid nodules, and their CRP, ESR was measured before surgery. Exclusion 
criteria included metabolic diseases, rheumatic diseases such as rheumatoid arthritis, SCL, microbial 
thyroiditis. 
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Data Collection 
Ninety-four patients were chosen and divided into two groups of 47 people, and the history of thyroid 
disease was studied in two benign and malignant groups. 
 
Histopathology 
The histopathological records of patients were retrospectively reviewed. Relevant cases had a 
cytological evaluation of thyroid nodules by fine-needle aspiration cytology (FNAC). Aspiration was performed 
on an outpatient basis without local anesthesia using a 22-gauge disposable needle, a disposable plastic 10 ml 
syringe fitted in a 22-gauge disposable needle. The resulting smears were fixed in the air with alcohol and 
stained in the pathology laboratory using May-Grunewald-Giemsa, Hematoxylin-Eosin, and Papanicolaou 
methods were examined by a pathologist. The results of needle aspiration were classified according to the 
appropriate indicators mentioned in benign, suspicious, malignant, insufficient, or non-specific groups [19]. 
 
Biochemical Assays 
ESR (mm/L) and CRP (mg/L) measurement methods were based on the standard laboratory methods 
as described elsewhere. In patients who were candidates for thyroid surgery, ESR / CRP was measured before 
surgery. 
 
Statistical Analysis 
ESR and CRP were measured before surgery and were compared by independent t-test in two groups 
of case and control. At a confidence level, 95% of the data were analyzed using IBM SPSS Statistics 20 
software. Factors such as age, sex, and history of thyroiditis were also compared in two groups (chi-square). 
The independent t-test was used to compare age. 
 
Ethical Clearance 
This investigation was approved by the Research Ethics Committee (Protocol No. 
IR.MUQ.REC.1395.121) and informed consent was obtained from patients. The patients were assured that 
their information will be confidential and will be used only for research purposes. 
 
Results 
According to the obtained results and as shown in Table 1, the mean age of the patients in the benign 
(control) group was 42.28 ± 13.43 (minimum – 22 years and maximum 70 years) and in the malignant group 
(case) was 42.20 ± 16.32 (minimum – 20 years and maximum 85 years), which was not significantly different 
(p=0.350). There was no significant difference in the mean of ESR and CRP in benign and malignant groups 
(p=0.800) (Table 1). 
 
Table 1. Clinic histopathological characteristics according to pathological results. 
 Groups  
Variables Malignant Benign p-value 
Age (Years) 45.20 ± 16.32 42.28 ± 13.43 0.350 
Gender - Female (N/%) 39 (83.0) 39 (83.0) 1.00 
ESR 13.54 ± 8.09 13.03 ± 7.80 0.800 
CRP 4.92 ± 5.88 4.92 ± 4.91 0.993 
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The rate of thyroiditis in both benign and malignant groups were evaluated and compared. In the 
benign group in the pathological report, 15 patients (31.9%) had a history of Hashimoto thyroiditis, while in 
the malignant group, a history of Hashimoto's thyroiditis was reported in 20 patients (42.6%), there was no 
significant difference between the two groups (p=0.216) (Table 2). 
 
Table 2. Frequency of patients with a history of thyroiditis in benign and malignant groups. 
 Group  
History of Thyroiditis Benign Malignant p-value 
 N (%) N (%)  
Yes 15 (31.9) 20 (42.6) 0.216 
No 32 (68.1) 27 (57.4)  
 
In the malignant group, 6 patients (12.8%) had capsular invasion, and 11 patients (23.4%) had vascular 
invasion and 9 (19.2%) patients had lymphatic metastases. The type of tumor was PTC in all patients in the 
malignant group. In the malignant group, the patients were divided into two groups according to the presence 
or absence of thyroiditis (Table 3). 
 
Table 3. Comparison of ESR and CRP in the malignant group. 
 History of Thyroiditis  
Variables Yes No p-value 
 Mean (SD) Mean (SD)  
ESR 12.75 ± 8.19 14.13 ± 8.24 0.665 
CRP 5.09 ± 5.26 4.80 ± 47.6 0.904 
 
The mean ESR in the group reported in their pathological history of thyroiditis was 19.8 ± 7.12 and 
in the group with no history of thyroiditis, it was 24.8 ± 14.4. The mean ESR of the two groups showed no 
significant difference (p=0.665). 
The mean CRP was also compared in the two groups: 5.09 ± 5.26 in the thyroid group and 6.47 ± 
4.80 in the non-thyroid group. No significant difference between mean CRP was observed (p=0.904). 
In the malignant group, the mean tumor size in the group with a history of thyroiditis was 
significantly less than that in the non-thyroid group (17.64 ± 9.31 vs. 40.16 ± 28.81, p=0.009). 
The association between ESR and CRP, ESR / CRP and tumor size, ESR / CRP and age in each 
group were analyzed using Pearson correlation test. The association between ESR and CRP, ESR / CRP and 
tumor size, ESR / CRP and age in each group as well as in the whole patients were evaluated using Pearson 
correlation test, which showed a positive association between ESR age and ESR (p=0.024, r = 0.375). In the 
malignant group, a negative correlation was found between the age and the rate of CRP (p=0.027, r = -0.441), 
and in the total patients between the age and the rate (ES = 0.043 r = -0.256). 
 
Discussion 
Epidemiological studies link the relationship between chronic inflammation and thyroid cancer risk 
factors, such as Hashimoto's thyroiditis [20]. In our research, the factors of ESR and CRP were examined. 
According to the results, there was no statistically significant difference between the groups in the level of ESR 
and CRP factors. Our results did not find a link between levels ESR and CRP in patients with benign and 
malignant thyroid nodules, which contradicts the few studies previously investigating this association. 
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Despite our study results, previous authors showed a different ESR expression and CRP between PTC 
and nodular goiter and it was demonstrated that in patients with PTC, the mean ESR and CRP level were 
lower than nodular goiter [17]. The difference in the results of ESR / CRP can be due to the difference in the 
type and volume of the sample of the two studies and the genetic differences between the two populations 
[17]. 
The history of thyroiditis in the malignant group was higher than the benign group. So it seems that 
thyroiditis was a risk factor for thyroid cancer in our study. However, no significant difference between the two 
groups (p=0.216) was found, which is in line with the previous literature report [19]. However, in the study of 
Bradly et al., Hashimoto thyroiditis was higher (40%) in papillary cancer than benign thyroid nodules [21]. 
It was found that in the malignant group, sub-analyzes were performed and ESR / CRP was compared 
in a group with a history of thyroiditis or a group that did not. The mean of ESR of the two groups not show a 
significant difference. The mean CRP was also compared in two groups, with a history of thyroid and no 
significant difference was found. The relationship between ESR and CRP, ESR / CRP and ESR / CRP tumor 
size and age in each group were analyzed using Pearson correlation test. In the benign group, there was a 
significant correlation between ESR and ESR and in the malignant group, there was a significant difference 
between age and CRP and in the total number of patients between the age and ESR. In line with these results 
and in the study of Hou et al., a positive correlation between ESR and CRP was found [17]. 
In this study, in the malignant group, the type of tumor was PTC in all patients. It is suggested that 
in future studies, the association between the level of ESR / CRP and other inflammatory factors such as IL-
1.6 with other types of thyroid cancers, such as follicular, modular, ana-plastic and thyroid lymphoma, should 
be considered. It is also suggested that further studies are needed to investigate the relationship between the 
level of anti-thyroid antibodies such as TgAb and TPOAb with the type of nodule (benign with malignant) and 
the size of the nodule and in the case of malignant nodules, the association of these antibodies with nodule 
invasion into thyroid capsules, blood vessels, lymph nodes, and prognosis and patient survival should be 
considered. 
Factors such as ESR and CRP that are acute phase reactants and their levels increase in cases of acute 
inflammation may not increase significantly in chronic inflammatory conditions and malignancies. In this 
study, the malignant tumor type is PTC in all cases and it is suggested that in future studies, the relationship 
between ESR / CRP level and other inflammatory factors such as IL-1.6 with other types of thyroid cancers 
should be considered. It is suggested that further studies be conducted to investigate the relationship between 
the level of anti-thyroid antibodies, such as TgAb and TPOAb, with the type of nodule (benign with 
malignant) and the size of the nodule. In the case of malignant nodules, the association between these 
antibodies and the invasive behavior of the nodule and proptosis and the survival rate of the patients are 
examined. 
The factors such as income level, alcohol consumption history, Metastasis, diagnostic, and treatment 
method affect the survival level, which can be a limitation in the present study. On the other hand, the tumor 
type in all patients was PTC in the malignant group, while the relation between ESR/CRP level and other 
inflammatory factors such as Il-1.6 and other thyroid cancers such as Follicular, modular, Anaplastic and also 
thyroid lymphoma can be studied. 
The relation between anti-thyroid antibodies such as TgAb and TPOAb and nodule type (benign and 
malignant) was not studied. In malignant nodules, the relation between mentioned antibodies and nodule 
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invasion of the thyroid capsule and thyroid and blood vessels, lymph and nerves, as well as prognosis and 
survival rate of patients, were not considered. 
 
Conclusion 
Factors such as ESR and CRP that are considered acute phase reactors and their levels increase in 
acute inflammatory conditions may not increase significantly in chronic inflammatory and malignant 
conditions. 
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